Investment Summary

GIMV Invests In Precirix

On November 15, 2018, private equity firm GIMV invested in life science company Precirix

Investment Highlights
  • This is GIMV’s 18th transaction in the Life Science sector.
  • This is GIMV’s 39th transaction in Belgium.

Investment Summary

Date 2018-11-15
Target Precirix
Sector Life Science
Investor(s) GIMV
Deal Type Venture

Target

Precirix

Brussels, Belgium
Precirix is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline. Precirix’ technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy. Precirix was founded in 2014 and is based in Brussels, Belgium.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

GIMV

Antwerp, Belgium

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1980
PE ASSETS 2.0B EUR
Size Large
Type Sector Agnostic
DESCRIPTION

GIMV is a Belgium based public investment company focused on private equity and venture capital investments in tech-based businesses. GIMV's private equity practice operates through its Corporate Investment unit and targets management buyouts, buy-ins, and growth capital financings of companies with annual sales between EUR15 and EUR150 million. For buyout opportunities GIMV generally takes a majority stake in businesses and for growth capital needs, GIMV takes a minority position. GIMV does not invest in publicly held companies or turnaround situations. GIMV's geographic focus is within Belgium, Netherlands, Germany, and France. GIMV also invests in Russia through Eagle Capital Partners, a partnership with KBC Private Equity. GIMV was formed in 1980 and is headquartered in Antwerp with additional offices in The Hague, Frankfurt, Munich, and Paris.


DEAL STATS #
Overall 127 of 170
Sector: Life Science M&A 18 of 24
Type: Venture M&A Deals 34 of 39
Country: Belgium M&A 39 of 50
Year: 2018 M&A 11 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-30 La Comtoise

Louhans, France

La Comtoise develops and supplies tailor-made cheese solutions which are integrated into prepared foods such as breaded escalopes (cordons bleus), grilled ham and cheese sandwiches (croque-monsieur), sandwiches and hamburgers. La Comtoise was founded in 1994 and is based in Louhans, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-11-16 Groupe Claire

Paris, France

Groupe Claire designs, manufactures, and supplies flow-control and smart equipment for water distribution networks. Groupe Claire was founded 2001 and is based in Paris, France.

Buy -